Edward John Benz
Member of Research Advisory Board & Independent DirectorDr. Edward John Benz, Jr., M.D., served as an Independent Director of Renovacor, Inc. since September 2021. He had been an Independent Director of Deciphera Pharmaceuticals, Inc. since October 6, 2016 until June 11, 2024. He has been an Independent Director of Massachusetts Life Sciences Center since August 2011. He serves as Director at CoRegen Inc. He has been a Member of Research Advisory Board at Candel Therapeutics, Inc. since April 2021. Dr. Benz also served as a member of the board of directors of Old Renovacor (as defined below) from July 2017 until September 2021. He serves as a Member of Advisory Board at Kernal Biologics, Inc. He is Independent Director at Candel Therapeutics, Inc. since September 2017. He had been Director at F-star Therapeutics, Inc. since December 2020. He serves as a Member of Scientific Advisory Board of Cardiokine, Inc. and served as its Director. Dr. Benz serves as a Member of Clinical Advisory Board at RS2 Healthcare Partners since January 2019. He is Director at f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H since February 2020. He is retired as president and chief executive officer (CEO) of Dana-Farber Cancer Institute in 2017. He is the President and CEO Emeritus, Dana-Farber Cancer Institute and a member of the Dana-Farber Cancer Institute Board of Directors. Dr. Benz is an expert in blood disorders and is board certified in both hematology and internal medicine. He is an active clinical hematologist and a National Institutes of Health (NIH) funded researcher with a focus on the molecular basis and genetics around inherited blood disorders. From November 2000 until his retirement in October 2016, Dr. Benz served as President and CEO Emeritus of Dana-Faber Cancer Institute and the Richard and Susan Smith Professor of Medicine and Professor of Genetics, professor of Pediatrics and faculty dean for Oncology Emeritus at Harvard Medical School. Prior to his role at Dana-Farber, Dr. Benz served as chairman for the Department of Medicine and Sir William Osler Professor of Medicine at Johns Hopkins University School of Medicine, as well as physician in chief at Johns Hopkins Hospital. Dr. Benz currently serves on the boards of directors of Knowledge to Practice, Incorporated since September 2015, Deciphers Pharmaceuticals since July 2019, Candel Therapeutics (formerly known as Advantagene) since August 2018 and F-Star Therapeutics since December 2019. He has also served on the board of directors of Xenetic Biosciences, Inc., a publicly traded biopharmaceutical company, as well as non-profit organizations, including the Rockefeller University and MDI Biological Laboratory. From March 2002 to June 2016, Dr. Benz served as associate editor of the New England Journal of Medicine. Dr. Benz has also served as President of the American Society of Hematology, the Association of American Cancer Institutes, the American Society for Clinical Investigation, the American Clinical and Climatological Society and the Friends of the National Institute of Nursing Research. Dr. Benz has authored more than 300 articles, books, reviews and abstracts and has received numerous awards. He received Bachelor of Arts degree from Princeton University, an M.D. degree magna cum laude, from Harvard Medical School in 1973 and received his training at Brigham and Women's Hospital and the National Institutes of Health. Dr. Benz holds an M.A. Degree (privatum) from Yale University. Dr. Benz is a clinically active internist with special expertise in inherited anemias and diseases of the red cell and is a Fellow of the American College of Physicians.
Positions
- Company NameCandel Therapeutics, Inc.Stock CodeCADLPositionMember of Research Advisory Board & Independent DirectorColleagues
- PTPaul-Peter TakPresident, CEO & Director
- PBPaul B. ManningIndependent Chairman
- CSCharles SchochSenior VP, CFO, Treasurer & Secretary
- FBFrancesca BaroneChief Scientific Officer
- STSeshu TyagarajanChief Technical & Development Officer
- TJTheodore JenkinsVice President of Investor Relations & Business Development
- RMRenee M. GaetaIndependent Director
- NLNicoletta LoggiaIndependent Director
